Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 371 to 380 of 797

TitleReference numberPublishedLast updated
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Naldemedine for treating opioid-induced constipationTA651
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaTA649
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA648
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)TA646
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)TA647
Avelumab with axitinib for untreated advanced renal cell carcinomaTA645
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641

Results per page

  1. 10
  2. 25
  3. 50
  4. All